following a resubmission:
oritavancin (Tenkasi®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
SMC restriction: patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection who are eligible for early discharge. Use should be on the advice of local microbiologists or specialists in infectious disease.
In two randomised, phase III, double-blind studies of patients with ABSSSI, oritavancin was non-inferior to a glycopeptide antibiotic for clinical cure at the end of treatment in the clinically evaluable population.
Medicine details
- Medicine name:
- oritavancin (Tenkasi)
- SMC ID:
- SMC2285
- Indication:
For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
- Pharmaceutical company
- Menarini Pharmaceuticals UK
- BNF chapter
- Skin
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 09 May 2022